Tolerogenic dendritic cells and TLR4/IRAK4/NF-κB signaling pathway in allergic rhinitis DOI Creative Commons

Chenglin Kang,

Xiaomei Li,

Peng Liu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 17, 2023

Dendritic cells (DCs), central participants in the allergic immune response, can capture and present allergens leading to inflammation immunopathogenesis of rhinitis (AR). In addition initiating antigen-specific responses, DCs induce tolerance modulate homeostasis. As a special type DCs, tolerogenic (tolDCs) achieve mainly by suppressing effector T cell responses inducing regulatory (Tregs). TolDCs suppress modulating tolerance, thereby reducing symptoms AR. Activation TLR4/IRAK4/NF-κB signaling pathway contributes release inflammatory cytokines, inhibitors this production tolDCs alleviate responses. This review focuses on relationship between with

Language: Английский

Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis DOI
Nan Wang, Jia Song,

Shi‐Ran Sun

et al.

Allergy, Journal Year: 2024, Volume and Issue: 79(5), P. 1230 - 1241

Published: Feb. 25, 2024

Identifying predictive biomarkers for allergen immunotherapy response is crucial enhancing clinical efficacy. This study aims to identify such in patients with allergic rhinitis (AR) undergoing subcutaneous (SCIT) house dust mite allergy.

Language: Английский

Citations

9
Vitamin D and allergic diseases DOI Creative Commons

Panyu Zhang,

Qingxiu Xu, Rongfei Zhu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 4, 2024

In recent years, the relationship between vitamin D and allergic diseases has received widespread attention. As a fat-soluble vitamin, plays crucial role in regulating immune system may influence onset progression of such as atopic dermatitis, rhinitis, asthma. To understand underlying mechanisms, we have summarized current research on association diseases. We also discuss impact its course diseases, particularly focusing how supplementation affects treatment outcomes these conditions. aim to provide theoretical basis practical guidance for optimizing management by modulating levels.

Language: Английский

Citations

8
Roads to remission: evolving treatment concepts in type 2 inflammatory diseases DOI Creative Commons
Marek Lommatzsch, Katharina Blümchen, Lisa A. Beck

et al.

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 80, P. 103050 - 103050

Published: Jan. 8, 2025

Language: Английский

Citations

1
Rapid food desensitization associated with omalizumab before oral immunotherapy DOI
Bruna Giavina-Bianchi, Pedro Giavina‐Bianchi

World Allergy Organization Journal, Journal Year: 2025, Volume and Issue: 18(2), P. 101032 - 101032

Published: Jan. 28, 2025

Language: Английский

Citations

1
Mucosal immunity and rheumatoid arthritis: An update on mechanisms and therapeutic potential DOI Creative Commons
Yuchen Yang,

Congmin Xia,

Chuanhui Yao

et al.

Autoimmunity Reviews, Journal Year: 2025, Volume and Issue: 24(5), P. 103775 - 103775

Published: Feb. 13, 2025

Rheumatoid Arthritis (RA) is a persistent autoimmune inflammatory disorder that arises from the intricate interaction between genetic predisposition and environmental influences. The progression of RA can be delineated into four distinct phases: initially, influence risk factors; followed by emergence systemic autoimmunity; subsequently, an asymptomatic phase; ultimately, manifestation clinical arthritis. Recently, role mucosal immunity in has gained significant attention research. Evidence published studies suggests not only influences onset but also plays crucial its progression. Scholars have begun to unravel links barriers gastrointestinal tract, respiratory system, oral cavity. Specifically, shifts microbiota, dysfunction barriers, abnormal activation immune tissues are all implicated pathogenesis RA.Despite this growing body knowledge, comprehensive review therapeutic implications yet conducted. This emphasizes driving abnormalities development autoimmunity rheumatoid arthritis (RA). It further explores potential RA, as well issues challenges need addressed current research field, providing new perspective targets for prevention treatment RA.

Language: Английский

Citations

1
A Mn Al double adjuvant nanovaccine to induce strong humoral and cellular immune responses DOI
Nan Qiao, Hairui Wang, Yanhua Xu

et al.

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 358, P. 190 - 203

Published: May 4, 2023

Language: Английский

Citations

21
Allergen immunotherapy for allergic asthma: The future seems bright DOI Creative Commons
Zuzana Diamant, Maurits van Maaren, Antonella Muraro

et al.

Respiratory Medicine, Journal Year: 2023, Volume and Issue: 210, P. 107125 - 107125

Published: Jan. 23, 2023

Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and rhinitis. AIT has been shown to restore allergen immune tolerance, can modify both early late-onset allergen-specific hyperreactivity, helps achieve disease control/remission prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) in a large group patients with HDM-driven further underscored its unique potential as well confirmed previous pollen AIT. More widespread use this treatment select patient populations should move promising field. In mini-review, we discuss updates insights based world data.

Language: Английский

Citations

18
The Role of Regulatory T Cells in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2024 DOI Open Access
Leticia Martín‐Cruz, Cristina Benito‐Villalvilla, Sofía Sirvent

et al.

International Archives of Allergy and Immunology, Journal Year: 2024, Volume and Issue: 185(5), P. 503 - 518

Published: Jan. 1, 2024

Allergy represents a major health problem of increasing prevalence worldwide with high socioeconomic impact. Our knowledge on the molecular mechanisms underlying allergic diseases and their treatments has significantly improved over last years. The generation allergen-specific regulatory T cells (Tregs) is crucial in induction healthy immune responses to allergens, preventing development worsening diseases.

Language: Английский

Citations

8
Allergen immunotherapy for allergic asthma DOI
J. Christian Virchow, Oliver Pfaar, Marek Lommatzsch

et al.

Allergologie select, Journal Year: 2024, Volume and Issue: 8(01), P. 6 - 11

Published: Jan. 1, 2024

Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) an essential component in armamentarium personalized therapy. Subcutaneous AIT (SCIT) or sublingual (SLIT) offer possibility to prevent patients with allergic rhinitis (reduction risk developing asthma) and achieve remission asthma. Accordingly, should always be considered a documented, clinically relevant allergy. However, precise phenotyping patient prerequisite for success

Language: Английский

Citations

6
Allergen immunotherapy combined with Notch pathway inhibitors improves HDM-induced allergic airway inflammation and inhibits ILC2 activation DOI Creative Commons
Yu Tong, Lei Wang, Lingya Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14

Published: Feb. 2, 2024

Introduction Group 2 innate lymphoid cells (ILC2s) play a crucial role in house dust mite (HDM)-induced allergic inflammation, and allergen immunotherapy (AIT) holds promise for treating the disease by reducing frequency of ILC2s. Despite significant progress AIT diseases, there remains need to improve control symptoms. Methods We investigated synergistic effect Notch signaling pathway subcutaneous (SCIT) airway inflammation mice their impact on ratio ILC2s lung tissues. This was achieved establishing HDM-induced disorders (HAAD) model SCIT model. Additionally, we conducted vitro investigations into secretory function activated using fluorescence-activated cell sorting. Furthermore, explored coactivation with sorting from tissues after modeling. Results Previously, our group demonstrated that inhibitors can reduce mice. induces lineage plasticity mature In this study, showed alleviates suppresses induced HDM. Interestingly, combined γ-secretase inhibitor (GSI), an pathway, significantly inhibited ILC2s, reduced suppressed Th2-type responses mouse HDM-challenged or without were treated GSI , found dramatically secretion type inflammatory factors Discussion These findings suggest be used as adjuvant therapy may hold potential treatment value cooperative during early AIT.

Language: Английский

Citations

6